Stephen joined the Francis Crick Institute in 2023 as Chief Business Officer.
Stephen brings over 20 years of experience in life sciences research and development organisations spanning academia, biotech and global big pharma, with extensive expertise in strategic and portfolio management, business development, partnerships and collaborations.
Stephen joined the Crick from the Coalition for Epidemic Preparedness Innovations (CEPI), where as Director of Strategy and Portfolio and a member of the Leadership Team he was responsible for driving development and delivery of CEPI’s strategic objectives, including strategic planning, portfolio governance, monitoring and evaluation.
Prior to CEPI, Stephen served as Global Head of Corporate Strategy and a member of the Executive Committee of Stallergenes Greer, an allergy-focused specialty biopharmaceutical company. He also previously held senior corporate and R&D strategy positions with GlaxoSmithKline, as well as scientific and business management positions across academia and industry, including roles in clinical study management, business development, and management consulting.
Stephen holds a BSc with first class honours in Biochemistry from the University of Liverpool, a PhD in Biochemistry from the University of Leeds and an MBA with distinction from Imperial College Business School.